Sun Pharmaceutical Industries shares closed at Rs 591.60, rising 2.22 percent after sources told CNBC-TV18 that the US Food and Drug Administration is expected to inspect company's Halol facility for 2 weeks.
The re-inspection of plant by the US Food and Drug Administration is likely to begin on February 12 and end on February 23, according to reports.
Sources said the US FDA inspection dates could change on account of technicalities.
In December 2015, the USFDA had issued a warning letter to Halol unit (Gujarat), which accounts for around 20 percent of US Sales for Sun Pharma.
The plant was re-inspected by USFDA in November-December 2016 & issued 9 observations.